Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin/Laropiprant for Oxidative Stress in Hypercholesterolemia
NCT01071525Phase 3
Key facts
- Status
- Unknown
- Start
- Apr 2010
- Primary completion
- Aug 2010
- Countries
- 1
- Sponsor
- Rambam Health Care Campus
- Modality
- Small Molecules
- Drugs
- niacin
- Conditions
- hypercholesterolemia
01
Overview
Phase 3, open-label trial of niacin in hypercholesterolemia, sponsored by Rambam Health Care Campus. Primary endpoint: Effect on oxidative stress at 12 weeks. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Adults with hypercholesterolemia and HDL < 40 mg/dL, excluding those on fibrates or who are pregnant/breastfeeding.
04
Endpoints
Primary
Effect on oxidative stress
Beyond the preview
Go deeper on NCT01071525.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071525.